LXRX - Director of Lexicon Pharmaceuticals Makes $1.10M Buy | Benzinga
Raymond Debbane, Director at Lexicon Pharmaceuticals (NASDAQ:LXRX), reported a large insider buy on October 12, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Debbane purchased 1,000,000 shares of Lexicon Pharmaceuticals. The total transaction amounted to $1,103,956.
Lexicon Pharmaceuticals shares are trading up 7.69% at $1.12 at the time of this writing on Friday morning.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Importance of Insider Transactions
Insider transactions shouldn't be used primarily to make an investing decision, however an ...